Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For chronic kidney disease (CKD) on dialysis. Sold as Sensipar. Every FDA application for this active ingredient: 1 branded and 17 generic.
As of Nov 15, 2026, FDA lists 18 applications for Cinacalcet Hydrochloride (sold as Sensipar), first approved Mar 8, 2004, with 3 new uses approved and 0 published complete response letters.
First approved: Mar 8, 2004
Applications: 18
New uses approved: 3
Complete response letters: 0
Medicare spending, 2025: $72.1M
First approved in the EU: Oct 22, 2004
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
RegparaDrugs with a new additional indication and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma, and hypercalcemia in… · Kyowa Hakko Kirin Co., Ltd. · Feb 21, 2014
Clinical Trials
3 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Amgen
Cipla
Strides Pharma
Lupin
Accord Hlthcare
Zydus Pharms USA Inc